25 17

Cited 0 times in

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Authors
 Seok Jin Kim  ;  Dok Hyun Yoon  ;  Jin Seok Kim  ;  Hye Jin Kang  ;  Hye Won Lee  ;  Hyeon-Seok Eom  ;  Jung Yong Hong  ;  Junhun Cho  ;  Young Hyeh Ko  ;  Jooryung Huh  ;  Woo-Ick Yang  ;  Weon Seo Park  ;  Seung-Sook Lee  ;  Cheolwon Suh  ;  Won Seog Kim 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.52(2) : 374-387, 2020-04 
Journal Title
 CANCER RESEARCH AND TREATMENT 
ISSN
 1598-2998 
Issue Date
2020-04
Keywords
Brentuximab vedotin ; CD30 ; Multiple myeloma oncogene-1 ; Non-Hodgkin lymphoma
Abstract
Purpose: The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30-expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit. Materials and methods: This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30-expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry. Results: High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15). Conclusion: BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.
Files in This Item:
T202004586.pdf Download
DOI
10.4143/crt.2019.198
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
Yang, Woo Ick(양우익) ORCID logo https://orcid.org/0000-0002-6084-5019
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180316
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links